Previous close | 1.6000 |
Open | 3.8000 |
Bid | 1.6000 |
Ask | 2.7500 |
Strike | 45.00 |
Expiry date | 2024-05-17 |
Day's range | 1.6000 - 3.9000 |
Contract range | N/A |
Volume | |
Open interest | 157 |
QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.
QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA reviewGermantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE